Analysis of 810 tweets from 25 unofficial ASCO representatives (Featured Voices) at ASCO 2024

被引:0
|
作者
Stratton, Owen [1 ]
Haslam, Alyson [2 ]
Prasad, Vinay [2 ]
机构
[1] Wayne State Univ, Sch Med, 540 E Canfield St, Detroit, MI 48201 USA
[2] Univ Calif San Francisco, 550 16th St,2nd Fl, San Francisco, CA 94158 USA
来源
JOURNAL OF CANCER POLICY | 2024年 / 42卷
关键词
ASCO; Twitter; Social media; Conference; Trials; Drug development; Drug approval; CONFLICTS-OF-INTEREST; TRIALS; IMPACT;
D O I
10.1016/j.jcpo.2024.100519
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Aim of the study: The American Society of Clinical Oncology (ASCO) hosts an annual conference and is one of the largest medical conferences globally. For ASCO 2024, they selected 25 Featured Voices, advertising them as individuals to follow on Twitter/X throughout the conference. The aim of this study was to characterize tweets from each of the 25 featured individuals. Brief summary of the methods: From May 16, 2024 through June 19, 2024 we filtered tweets by using the twitter advanced search tool and applying the following criteria in the tweet text: #ASCO OR #ASCO24 OR #ASCO2024. Tweets were classified as being about research (yes or no) and if media was included (yes or no). Additional information about research related tweets was gathered, such as whether the research was observational or interventional. If it was interventional, we characterized whether the tweet was supportive, critical, or neutral of the research. Results: We find that 229 (28.3 %) of 810 tweets commented on research. Of the 229 research related tweets, 136 (59.4 %) were related to interventional trials of which they were supportive 65.3 % of the time. Media was included in 280 (34.6 %) of 810 tweets. 219 were photos of a person and 80 were selfies. Conclusion: ASCO Featured Voices tweeted more photos, including selfies (n=299), than commentary about research (n=229). When research was referenced, individuals were rarely critical. Trials presented at ASCO have the ability to impact guidelines, so it is important that they are appraised critically and discussed in an unbiased way. How Featured Voices are chosen requires further scrutiny. Policy summary statement at the end: ASCO should disclose financial relationships in the future when selecting Featured Voices to represent the organization and provide insight.
引用
收藏
页数:5
相关论文
共 22 条
  • [21] Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program (vol 25, pg 299, 2024)
    King, Brett
    Soung, Jennifer
    Tziotzios, Christos
    Rudnicka, Lidia
    Joly, Pascal
    Gooderham, Melinda
    Sinclair, Rodney
    Mesinkovska, Natasha A.
    Paul, Carle
    Gong, Yankun
    Anway, Susan D.
    Tran, Helen
    Wolk, Robert
    Zwillich, Samuel H.
    Lejeune, Alexandre
    AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2024, 25 (04) : 689 - 689